Using rifaximin to improve liver transplant outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effect of perioperative oral rifaximin on early graft dysfunction in adult patients undergoing living donor liver transplantation. The study involves administering rifaximin 550 mg twice daily starting two weeks before surgery and continuing until one week post-operation. It aims to determine whether this antibiotic can reduce the incidence of early graft dysfunction, which is a significant complication associated with liver transplants. The trial will include 100 participants and is designed as an open-label randomized control study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All recipients (adults) undergoing living donor liver transplant in ILBS.

Exclusion Criteria:

* Negative consent

  * Hypersensitivity to Rifaximin
  * Patients undergoing retransplant
  * ALF, ACLF
  * Pediatrics patients
  * Patients on rifaximin

Where it's running

• Insitute of Liver and Biliary Sciences
  New Delhi, National Capital Territory of Delhi, India Recruiting

Study contacts

• Study coordinator: Tapan Kumar Pradhan, MS
• Email: tapan.ravi94@gmail.com
• Phone: 9970189001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Copper supplementation for people with cirrhosis

  This trial will try giving copper supplements to adults with cirrhosis who have low copper levels or signs of copper deficiency to see if liver-related health improves.

  Recruiting University of Washington · Seattle, Washington · NCT07471542

• Understanding how chronic liver disease patients with organ failure fare after non‑emergency hospital stays

  This study follows adults with chronic liver disease who are admitted to the hospital non-electively to see how their condition develops over six months when liver and/or other organs fail.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07270809

• Understanding social and health needs of people with chronic liver disease in outpatient care

  This project will see how common social needs are and whether adults with chronic liver disease want their outpatient providers to help with them.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07191886

• Endoscopic ultrasound shear wave elastography for measuring liver fibrosis

  This study will test whether endoscopic ultrasound shear wave elastography and attenuation imaging can estimate liver fibrosis compared with biopsy and FibroScan in adults with suspected MASLD or MASH.

  Recruiting at 3 sites Olympus Corporation of the Americas · Newport Beach, California and 2 other locations · NCT06592820

• Comparing intravenous and under-skin LAENNEC for alcoholic and non-alcoholic fatty liver disease

  This will test whether 10 ml intravenous LAENNEC given twice weekly for six weeks works better and is as safe as 4 ml subcutaneous LAENNEC in adults 19–70 with alcoholic or non‑alcoholic fatty liver disease.

  Recruiting Phase 3 Green Cross Wellbeing · Yongin-si · NCT06493799

• Gathering data on hepatomiR for liver disease outcomes

  This study is trying to see how a new test for liver disease can help doctors understand and predict serious problems in patients with chronic liver issues.

  Recruiting Karl Landsteiner University of Health Sciences · Sankt Pölten, Lower Austria · NCT06432582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.